收费全文 | 1251800篇 |
免费 | 94969篇 |
国内免费 | 1512篇 |
医药卫生 | 1348281篇 |
2018年 | 13382篇 |
2017年 | 10308篇 |
2016年 | 11182篇 |
2015年 | 12917篇 |
2014年 | 17923篇 |
2013年 | 27391篇 |
2012年 | 37525篇 |
2011年 | 39904篇 |
2010年 | 22960篇 |
2009年 | 22173篇 |
2008年 | 37698篇 |
2007年 | 40320篇 |
2006年 | 39908篇 |
2005年 | 39033篇 |
2004年 | 37489篇 |
2003年 | 35848篇 |
2002年 | 34768篇 |
2001年 | 55894篇 |
2000年 | 56868篇 |
1999年 | 47725篇 |
1998年 | 12447篇 |
1997年 | 11305篇 |
1996年 | 11706篇 |
1995年 | 11812篇 |
1994年 | 11025篇 |
1993年 | 10314篇 |
1992年 | 38128篇 |
1991年 | 37657篇 |
1990年 | 36418篇 |
1989年 | 35237篇 |
1988年 | 32648篇 |
1987年 | 32006篇 |
1986年 | 30496篇 |
1985年 | 28760篇 |
1984年 | 21900篇 |
1983年 | 19127篇 |
1982年 | 11302篇 |
1981年 | 10255篇 |
1979年 | 20878篇 |
1978年 | 15353篇 |
1977年 | 12706篇 |
1976年 | 11752篇 |
1975年 | 12743篇 |
1974年 | 15516篇 |
1973年 | 15297篇 |
1972年 | 14475篇 |
1971年 | 13516篇 |
1970年 | 12749篇 |
1969年 | 12033篇 |
1968年 | 11202篇 |
Vaccination prevents severe morbidity and mortality from COVID-19 in the general population. The immunogenicity and efficacy of SARS-CoV-2 vaccines in patients with antibody deficiency is poorly understood.
ObjectivesCOVID-19 in patients with antibody deficiency (COV-AD) is a multi-site UK study that aims to determine the immune response to SARS-CoV-2 infection and vaccination in patients with primary or secondary antibody deficiency, a population that suffers from severe and recurrent infection and does not respond well to vaccination.
MethodsIndividuals on immunoglobulin replacement therapy or with an IgG less than 4 g/L receiving antibiotic prophylaxis were recruited from April 2021. Serological and cellular responses were determined using ELISA, live-virus neutralisation and interferon gamma release assays. SARS-CoV-2 infection and clearance were determined by PCR from serial nasopharyngeal swabs.
ResultsA total of 5.6% (n?=?320) of the cohort reported prior SARS-CoV-2 infection, but only 0.3% remained PCR positive on study entry. Seropositivity, following two doses of SARS-CoV-2 vaccination, was 54.8% (n?=?168) compared with 100% of healthy controls (n?=?205). The magnitude of the antibody response and its neutralising capacity were both significantly reduced compared to controls. Participants vaccinated with the Pfizer/BioNTech vaccine were more likely to be seropositive (65.7% vs. 48.0%, p?=?0.03) and have higher antibody levels compared with the AstraZeneca vaccine (IgGAM ratio 3.73 vs. 2.39, p?=?0.0003). T cell responses post vaccination was demonstrable in 46.2% of participants and were associated with better antibody responses but there was no difference between the two vaccines. Eleven vaccine-breakthrough infections have occurred to date, 10 of them in recipients of the AstraZeneca vaccine.
ConclusionSARS-CoV-2 vaccines demonstrate reduced immunogenicity in patients with antibody deficiency with evidence of vaccine breakthrough infection.
相似文献